Bonus BioGroup
Press Room

Press Releases

Press Releases

Bonus BioGroup Press Releases

The success of Bonus BioGroup’s MesenCure in the treatment of acute pneumonia will be presented at the annual meeting of the International Society for Cell & Gene Therapy (ISCT)


Bonus BioGroup (TASE: BONS.TA), a clinical-stage Israeli biotechnology company, engaged in research and development of biomedical tissue engineered and cell therapy products, is pleased to announce that the Company has been invited to present its technological breakthrough in its promising preliminary pre-clinical results of the development of MesenCure, novel, cell-based drug product (hereinafter: "the Study"), developed specifically for the treatment of life-threatening acute respiratory distress in COVID-19 and pneumonia patients, to 1,800 scientists, physicians, and public opinion leaders from around the world, attending the conference of the International Society for Cell & Gene Therapy - "ISCT". The ISCT conference will be held May 28-29, 2020, via video broadcast.

Successful treatment of acute pneumonia, demonstrating that following the administration of MesenCure, the treated lung appeared as a healthy lung


Bonus BioGroup (TASE: BONS.TA), a clinical-stage Israeli biotechnology company engaged in research and development of biomedical tissue engineered and cell therapy products, is pleased to announce the preliminary pre-clinical study results of a novel, unique drug product  MesenCure (hereinafter: "the Study"), developed by the Company specifically for the treatment of life-threatening acute respiratory distress in COVID -19 and pneumonia patients, which has demonstrated the successful treatment of acute pneumonia in an animal model. This success is reflected in the fact that following the treatment with MesenCure, the microscopic appearance of the treated lungs was similar to a healthy lung, and a significant improvement in additional related parameters was achieved.

Bonus BioGroup is pleased to announce that on April 19, 2020, it initiated a preclinical study (“the Study”) of a unique drug product termed MesenCure, specially developed by the Company for the treatment of acute and life-threatening respiratory distress in coronavirus (COVID-19) and pneumonia patients. The drug MesenCure consists of activated Mesenchymal Stromal Cells (“MSCs”) that are isolated from the adipose tissue of healthy donors. The activation of the MSCs before their administration is intended to boost their therapeutic efficacy while maintaining their excellent safety profiles and is achieved by exposing them to an innovative combination of chemical, biological, and physical conditions. Following intravenous transfusion, the activated cells are expected to reach the lungs and act to reduce inflammation, promote the regeneration of the diseased lung tissue, and alleviate respiratory and other symptoms.

Bonus BioGroup is pleased to announce the approval of the European patent by the European Patent Office (EPO), which provides Bonus Therapeutics, a subsidiary of Bonus BioGroup, exclusive protection for the development, utilization and commercialization of Bonus’ live bone graft product in Europe, for the treatment of bone deficiencies (hereafter: “the European patent”), applied by injection or by any other manner.

For the first time ever, arm and leg were healed using a bone graft grown outside patient’s body, in an orthopedic clinical trial for filling extensive critical bone void in limbs

Bonus BioGroup raises investment in the amount of NIS 18 million (USD 5 million), at a price of 60 Agorot per share

Bonus BioGroup Secures Exclusivity in the U.S. over Manufacturing and Commercialization of Live Bone Graft

Israel Innovation Authority approves support to the Company's R&D budget for 2017

Company Obtains U.S. Patent Notice of Allowance for Angiogenic Technology

For the first time ever, bone graft grown outside patient’s body is implanted in his leg, in an orthopedic clinical trial for filling extensive critical bone defects in limbs

Bonus BioGroup Receives Israeli Ministry of Health Approval for Clinical Trial Testing Second Generation Injectable Human Bone Graft for Maxillofacial Repair

Bonus BioGroup Raises 4 Million NIS at 70 Agorot per Share
Fundraised a total of 18 million NIS at a price 18% higher than the average stock exchange and intends to register all of its shares for trade in the US, at the NASDAQ or NYSE.

Bonus BioGroup Expands Prospective Product Line

Successful Proof-Of-Concept Preclinical Study on the Development of Large Vascularized Human Bone Graft

One Week Following Receipt of Required Approvals for Second Clinical Trial

Bonus BioGroup Enrols First Three Subjects in Clinical Trial with Second Generation Live Injectable Bone Graft for Repair of Maxillofacial Deficiencies

Bonus BioGroup Announces Successful First Transplantation of Second-Generation Injectable Live Human Bone Graft in Clinical Trial for Maxillofacial Bone Repair

Bonus BioGroup announces today successful transplantation for the first patient in the Company's second clinical trial for the repair of maxillofacial bone deficiencies. The transplantation was performed a fortnight following collection of the patient's fat sample, and several weeks following the enrolment of the first three subjects.

Bonus BioGroup Announces Revolutionary Medical Breakthrough

Successful Outcome in First Clinical Trial: Safe, Rapid and Efficient Reconstruction of Maxillofacial Bone by the Company's Injectable Live Human Bone Graft was Achieved in All Subjects

Bonus BioGroup Announces Receipt of European GMP and International ISO-9001 Certification

Page 1 of 2

FOR MORE INVESTOR RELATION INFORMATION

Press Release, Announcements publication and more

Bonus BioGroup

Image

 

Terms of UsePrivacy Policy        

© 2020 Bonus BioGroup Ltd. All Rights Reserved. Designed By Netron Israel Ltd.